Related Articles
KRAS mutation in patients with metastatic colorectal cancer does not preclude benefit from oxaliplatin‑ or irinotecan‑based treatment
Antitumor activity of the dual PI3K/mTOR inhibitor gedatolisib and the involvement of ABCB1 in gedatolisib resistance in canine tumor cells
Helical and kinase domain mutations of PIK3CA, and their association with hormone receptor expression in breast cancer
Mutational landscape and potential therapeutic targets for sporadic pancreatic neuroendocrine tumors based on target next‑generation sequencing
Pilot investigation of the mutation profile of PIK3CA/PTEN genes (PI3K pathway) in grade 3 endometrial cancer